In a randomized double-blind trial of oral CU over 24 weeks, no significant differences were observed in biomarkers or related psychiatric scores compared to the placebo (Ringman et al., 2012)
Centocor), and adalimumab (Humira
At Well-Rooted, we believe in harnessing the power of peptides to help our patients achieve optimal health, and one of our absolute favorites is BPC-157
This is highly speculative because: Oral bioavailability differs between species Route of administration affects systemic exposure Species differences in peptide metabolism and clearance are unknown Current Practice Patterns Current practice patterns from unregulated sources typically involve: Subcutaneous injection: 0.25-0.5 mg once or twice daily, administered near injection sites for localized effects or abdominally for systemic distribution
Wound healing acceleration: The peptide promotes angiogenesis through VEGF upregulation, enhancing nutrient delivery and accelerating dermal wound closure in multiple animal and human tissue models
Steroids replace hormones and often come with long-term risks